Imidazoylalkyl substituted with a six membered nitrogen containing nitrogen containing heterocyclic ring
Disclosed is a compound of Formula 1.0: ##STR1## or a pharmaceutically acceptable salt or solvate thereof. Also disclosed are pharmaceutical compositions comprising a pharmaceutically acceptable carrier and an effective amount of a Compound of Formula 1.0.Further disclosed is a method of treating allergy (for example asthma), inflammation, hypertension, raised intraocular pressure (such as glaucoma)--i.e., a method of lowering intraocular pressure, sleeping disorders, states of hyper and hypo motility and acidic secretion of the gastrointestinal tract, hypo and hyperactivity of the central nervous system (for example, agitation and depression) and other CNS disorders (such as Alzheimers, Schizophrenia, and migraine) comprising administering an effective amount of a compound of Formula 1.0 to a patient in need of such treatment.
Latest Schering Corporation Patents:
Claims
1. A compound of the formula: ##STR63## or a pharmaceutically acceptable salt or solvate thereof, wherein: (A) R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are H;
- (B) R.sup.5 is selected from the group consisting of:
- (1) H;
- (2) C.sub.1 to C.sub.20 alkyl;
- (3) C.sub.3 to C.sub.6 cycloalkyl;
- (4) --C(O)OR.sup.7'; wherein R.sup.7' is the same as R.sup.7 defined below except that R.sup.7' is not H;
- (5) --C(O)R.sup.7;
- (6) --C(O)NR.sup.7 R.sup.8;
- (7) allyl;
- (8) propargyl; and
- (9) --(CH.sub.2).sub.q --R.sup.6, wherein q and R.sup.6 are as defined above, and when q is equal to 1, then R.sup.6 is not OH or SH; and
- (C) R.sup.7 and R.sup.8 are each independently selected from the group consisting of: H, C.sub.1 to C.sub.6 alkyl, and C.sub.3 to C.sub.6 cycloalkyl.
2. A compound of the formula: ##STR64## or a pharmaceutically acceptable salt or solvate thereof, wherein: (A) R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are H; and
- (B) R.sup.5 is selected from the group consisting of:
- (1) H; and
- (2) C.sub.1 to C.sub.6 alkyl.
3. A compound of the formula: ##STR65## or a pharmaceutically acceptable salt or solvate thereof, wherein: (A) R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are H; and
- (B) R.sup.5 is H.
4. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and an effective amount of a Compound of claim 1.
5. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and an effective amount of a Compound of claim 2.
6. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and an effective amount of a Compound of claim 3.
3491098 | January 1970 | Archer |
4324487 | April 13, 1982 | Bradshaw |
4404382 | September 13, 1983 | Gall |
4404387 | September 13, 1983 | Gall |
4431653 | February 14, 1984 | Wei |
4707487 | November 17, 1987 | Arrang |
4767778 | August 30, 1988 | Arrang et al. |
4925851 | May 15, 1990 | Houlihan |
4935417 | June 19, 1990 | Pascal et al. |
5010075 | April 23, 1991 | Pascal et al. |
5071859 | December 10, 1991 | Knudsen |
5091428 | February 25, 1992 | Pascal et al. |
5290790 | March 1, 1994 | Arrang |
0197840 | October 1986 | EPX |
0338939 | October 1989 | EPX |
0372125 | June 1990 | EPX |
- West Jr. et al., Journal of Neurochemistry, vol. 55, No. 5, pp. 1612-1616 (1990). Korte et al., Biochemical and Biophysical Research Communications, vol. 168, No. 3, pp. 979-986 (1990). RN 80101-09-3 For CA 96(1): 6760b (1981). Current Neurology, vol. 6, pp. 313-316 (1987). Schunack, CA 80(15): 828o/a (1973).
Type: Grant
Filed: Jun 1, 1995
Date of Patent: Aug 3, 1999
Assignee: Schering Corporation (Kenilworth, NJ)
Inventors: Neng-Yang Shih (North Caldwell, NJ), Michael J. Green (Skillman, NJ)
Primary Examiner: Ceila Chang
Attorney: Henry C. Jeanette
Application Number: 8/457,352
International Classification: A61K 31445; C07D40106;